Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Safety, Tolerability, and Preliminary Efficacy of Human Umbilical Cord Mesenchymal Stem Cell Injection Via Intravenous Infusion in Type 2 Diabetic Nephropathy: A Phase I/IIa Clinical Trial

NCT07769671 is registered in ClinicalTrials.gov with The First People's Hospital of Changzhou as lead sponsor.

NCT NCT07769671
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07769671 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Safety, Tolerability, and Preliminary Efficacy of Human Umbilical Cord Mesenchymal Stem Cell Injection Via Intravenous Infusion in Type 2 Diabetic Nephropathy: A Phase I/IIa Clinical Trial
Lead sponsor
The First People's Hospital of Changzhou
Phase
Phase 1/2
Overall status
Not yet recruiting
Start date
September 1, 2026
Completion date
August 31, 2029
Enrollment
49 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

diabetic nephropathy type 2